Document is current
Any future updates will be listed below
-
Authors
Westhoff, Christina C.
Ramaswamy, Annette
Kalder, Matthias
Lebeau, Annette
Sinn, Peter
Denkert, Carsten
- License Information
-
More Information
Article History
Accepted: 16 December 2022
First Online: 28 December 2022
Einhaltung ethischer Richtlinien
:
: C.C. Westhoff: Anneliese Pohl-Habilitationsförderung. A. Ramaswamy: Es bestehen keine Interessenkonflikte. M. Kalder: Mammograpy Screening (Lecture Fees, ohne Einfluss auf diesen Artikel). A. Lebeau: AstraZeneca (Consulting and Lecture Fees); Daiichi Sankyo (Consulting and Lecture Fees); MSD Sharp & Dohme (Consulting and Lecture Fees); Roche Pharma AG (Consulting and Lecture Fees; Study Support); Myriad Genetics (Lecture Fees); Novartis (Consulting and Lecture Fees); Diaceutics (Consulting Fees); QuIP GmbH (Consulting Fees). P. Sinn: Daiichi Sankyo (Consulting Fees); Roche Pharma AG (Consulting and Lecture Fees; Study Support); Diaceutics (Consulting and Lecture Fees). C. Denkert: AstraZeneca (Consulting Fees [e.g., advisory boards]); Daiichi Sankyo (Consulting Fees [e.g., advisory boards]); Lilly (Consulting Fees [e.g., advisory boards]); Molecular Health (Consulting Fees [e.g., advisory boards]); MSD Oncology (Consulting Fees [e.g., advisory boards]); Roche (Consulting Fees [e.g., advisory boards]); Sividon Diagnostics (Ownership Interest [stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds]); VMScope (Receipt of Intellectual Property Rights/Patent Holder, Royalty).
: Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
